glp 1 agonist anti inflammatory GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease 2024 Multiple Sclerosis Highlight -
Description
A new survey report from the International Foundation of Employee Benefit Plans reveals results from a group of Canadian employers regarding considerations and coverage for glucagon-like peptide-1 (GLP-1) drugs, which have historically been used to treat diabetes and are increasingly being used to treat obesity
It was the first drug officially approved for weight loss and paved the way for newer options
However, triple receptor agonism, or agonism/antagonism combinations, can be achieved not only though unimolecular triple agonists, but also by combining mono- and dual-agonists
10,11 REFERENCES 1
